Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Buy dildos.
Popular Articles

Ilaris® Recommended For European Approval As New Biologic Drug To Treat A Rare But Serious Group Of Auto-inflammatory Diseases
The biotechnology medicine Ilaris® (canakinumab) has passed another major milestone with a recommendation for approval in the European Union to treat patients with a life-long and potentially fatal auto-inflammatory disease called cryopyrin-associated periodic syndrome (CAPS). When approved, Ilaris will be the only treatment in the EU indicated for CAPS patients aged four years and older[1].
pharmacy online
Roche To Commence Phase III Trials With Innovative Treatment Designed To Lower Cardiovascular Risk In Diabetes Patients With Recent Heart Attack
Roche announced it will start Phase III clinical investigations for aleglitazar, its innovative PPAR co-agonist R1439 which is uniquely designed to reduce cardiovascular morbidity and mortality in high risk patients with type 2 diabetes. This decision is supported by data from the Phase II SYNCHRONY study published today in The Lancet(1) and announced at the American Diabetes Association meeting in New Orleans. The Phase III program is anticipated to start in the second half of 2009.
News of the day
'Death Receptors' Designed To Kill Our Cells May Make Them Stronger
It turns out that from the perspective of cell biology, Nietzsche may have been right after all: that which does not kill us does make us stronger. In a review article published in the June 2009 print issue of The FASEB Journal, scientists from the Mayo Clinic explain how cell receptors (called "death receptors") used by the body to shut down old, diseased, or otherwise unwanted cells (called "apoptosis") may also be used to make cells heartier when facing a wide range of illnesses, from liver disease to cancer.
Diagnostics

General Practices Need More Nurses, Australia

Boosting the number of practice nurses who work with GPs would help improve patient access to care, the AMA said today. AMA Federal President, Dr Andrew Pesce, today used GP Week to renew calls for the Government to increase support for nurses who work in general practices. A recent report funded by the Australian Primary Health Care Research Institute found practice nurses helped take pressure off GPs and increased access to care for patients. "Delegating some tasks to practice nurses frees up GPs to spend more time with patients. Practice nurses are able to perform a range of clinical tasks on behalf of doctors in areas such as diabetes and complex and chronic disease management and preventive screening," Dr Pesce said. "There are currently 8000 Practice nurses employed in around 65% of General Practices. The AMA believes every General Practice should be able to employ a practice nurse. "Only general practices in rural, regional and outer suburban practices are eligible for government general practice nurse subsidies. Removing these geographic restrictions would enable more practices to employ nurses. "The Government should also expand the scope of tasks nurses can perform on behalf of doctors under the Medicare Benefits Schedule (MBS)." Australian Medical Association


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009